REFRACTORY BURKITT LYMPHOMA
Clinical trials for REFRACTORY BURKITT LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY BURKITT LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY BURKITT LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…
Matched conditions: REFRACTORY BURKITT LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Promising lymphoma combo trial pulled before it began
Disease control TerminatedThis phase 2 trial was designed to test a combination of rituximab, venetoclax, and bortezomib in patients with diffuse large B-cell lymphoma that had come back or stopped responding to treatment. The goal was to see how many patients would have their tumors shrink or disappear. …
Matched conditions: REFRACTORY BURKITT LYMPHOMA
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-phase trial is testing whether combining two drugs—nivolumab (a monoclonal antibody) and lenalidomide (a chemotherapy-like drug)—can safely and effectively treat people with non-Hodgkin or Hodgkin lymphoma that has returned or is not responding to treatment. The study …
Matched conditions: REFRACTORY BURKITT LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New Three-Drug cocktail targets Hard-to-Treat lymphoma
Disease control OngoingThis early-phase study tests a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in 22 patients with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and see how well the body tolerates the c…
Matched conditions: REFRACTORY BURKITT LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated Jun 26, 2026 15:12 UTC